Qurexa Logo
Qurexa

Trust. Care. Deliver.

Back to Blog & Insights
Health

The age limit just dropped from 12 to five: what the new gene-editing decision means

Qurexa Editorial Team31 October 20267 min read 0 0
The age limit just dropped from 12 to five: what the new gene-editing decision means

What happened

On 30 October 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) announced that it has extended its approval of a gene-editing treatment called Casgevy. The treatment can now be used in children aged five and over who have severe sickle cell disease or transfusion-dependent beta-thalassaemia. Before this decision, the treatment was only approved in the UK for people aged 12 and over. The approval was granted on 29 October 2026 to Vertex Pharmaceuticals (Europe) Ltd. Casgevy has a long scientific name: exagamglogene autotemcel. Both of the conditions it treats are inherited. That means they are passed down through families, and they are caused by errors in the genes that tell the body how to make haemoglobin. Haemoglobin is the protein inside red blood cells that carries oxygen around the body. Julian Beach, the MHRA's Executive Director of Operations, said the approval means the treatment can now be used in eligible children from the age of five. He added that, as with all medicines, the MHRA will keep watching how safe and how effective it is. The MHRA also said the full prescribing document and the patient information leaflet would be published on its Products website within seven days of the approval.

Why this matters

About 15,000 people in the UK have a sickle cell disorder, according to the MHRA. Severe sickle cell disease can cause episodes of very bad pain, serious infections and anaemia, which is when the blood cannot carry enough oxygen. Beta-thalassaemia can cause severe anaemia too. The MHRA says people with the transfusion-dependent form often need a blood transfusion every three to five weeks, for their whole life, along with regular injections and medicines. That is the part worth sitting with. A transfusion every three to five weeks means roughly ten to seventeen hospital visits a year, every year. For a child, that is school missed, plans changed and a lot of needles. For a parent, it is time off work and a diary built around a hospital. So lowering the age limit from 12 to five is not a small administrative change. It means some children could be considered for this treatment several years earlier than before - during the years when they would otherwise be building up a long history of transfusions. It is also worth being clear about what has not been decided. An MHRA approval is about whether a medicine is allowed to be sold and used in the UK, based on evidence about its safety, quality and how well it works. It is a separate question whether the NHS will pay for it for a particular group of patients. The MHRA's announcement did not cover NHS funding, and families should not assume the two decisions are the same thing.

What the evidence actually says

The MHRA said its decision was based on its own assessment of the evidence on safety, quality and effectiveness. Its public announcement did not publish trial numbers, so we are not going to invent any here. What the MHRA did explain is how the treatment works, and it is worth understanding because it is unlike taking a tablet. First, stem cells are collected from the patient's own bone marrow. Stem cells are the cells that make new blood. Those cells are then taken to a laboratory, where a faulty gene is edited so that the body can start making haemoglobin that works properly. Before the edited cells go back in, the patient has what is called conditioning treatment. This prepares the bone marrow to accept them. The edited cells are then given back to the patient as an infusion. The MHRA notes that patients may need to stay in hospital while the edited cells settle in and begin producing red blood cells. This is a one-off procedure rather than a daily medicine, but it is a significant hospital process, not a quick appointment. The side effects listed by the MHRA include feeling sick, tiredness, fever and a higher risk of infection. The higher infection risk makes sense given the conditioning step, which affects the bone marrow where immune cells are made. One honest limitation: because this is a newer kind of treatment, the long-term picture is still being built. That is exactly why the MHRA said it will keep monitoring safety and effectiveness. Approval is not the end of the evidence-gathering; it is a point along the way.

Practical advice

If you or your child has sickle cell disease or beta-thalassaemia, here is a sensible way to use this news. **Do not change anything on your own.** If your child is on a transfusion schedule, or takes medicines to manage iron levels, keep going exactly as prescribed. A licensing decision about a different treatment is not a reason to miss an appointment or stop a medicine. **Ask your specialist team, not the internet.** Sickle cell and thalassaemia care in the UK is run through specialist centres. Your haematology team is the right place to ask whether this treatment could ever be relevant for your child, and what the NHS position is. Write your questions down before the appointment so you do not forget them under pressure. **Three useful questions to take with you:** Is my child the kind of patient this treatment is designed for? Is it available through the NHS for their age group right now? What would the process involve for us in practical terms, including time in hospital? **Be careful with claims online.** Gene therapy attracts a lot of excitement and some outright nonsense. If you read something dramatic, check whether it comes from the MHRA, the NHS, or a named specialist centre. Anyone offering you a gene-editing treatment outside the NHS, or asking for money up front, deserves a very sceptical look. **Report side effects if you have them.** Anyone in the UK can report a suspected side effect from a medicine through the MHRA's Yellow Card scheme. It is free, it takes a few minutes, and it is one of the main ways regulators spot problems early.

What to know

The MHRA has extended its approval of Casgevy, a gene-editing treatment, to children aged five and over with severe sickle cell disease or transfusion-dependent beta-thalassaemia. The previous lower limit was 12. The approval was granted on 29 October 2026 and announced on 30 October 2026. The treatment edits a faulty gene in the patient's own bone marrow stem cells so the body can make working haemoglobin. It involves collecting cells, editing them in a laboratory, conditioning treatment, and an infusion, with a possible hospital stay afterwards. Listed side effects include nausea, tiredness, fever and a raised risk of infection. About 15,000 people in the UK have a sickle cell disorder. People with transfusion-dependent beta-thalassaemia often need a transfusion every three to five weeks for life. The key thing to hold on to: approval by the MHRA is about whether a medicine can legally be used here. Whether the NHS funds it for a particular age group is decided separately, and the MHRA's announcement did not address that. If this matters to your family, your specialist haematology team is the place to get a straight answer. Sources: GOV.UK (MHRA), 'MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders', 30 October 2026, https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders; GOV.UK, Medicines and Healthcare products Regulatory Agency news listing, accessed 31 October 2026, https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency; Open Access Government, 'MHRA approves gene-editing treatment for children with serious blood disorders', 30 October 2026, https://www.openaccessgovernment.org/mhra-approves-gene-editing-treatment-for-children-with-serious-blood-disorders/216014/ This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. If you or your child has a blood disorder, speak to your specialist team before changing anything about your care.

#sickle cell#thalassaemia#gene therapy#MHRA#children's health#NHS

Related articles